NCT02267213 - Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 10, 2014

Primary Completion Date

July 9, 2015

Study Completion Date

July 9, 2015

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Lipotecan

Administer 40mg Lipotecan at D1, D8, D15 of each cycle.

Trial Locations (12)

307 Hospital of PLA, Beijin

Shanghai Cancer Hospital, Fudan University, Shanghai

Zhongshan Hospital, Fudan University, Shanghai

Nanjing Bayi Hospital, Nanjing

Chiayi Chang Gung Memorial Hosipital, Chiayi City

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

China Medical University Hosipital, Taichung

National Cheng Kung University Hospital, Tainan City

Mackay Memorial Hosipital, Taipei

National Taiwan University Hosipital, Taipei

Taipei Veterans General Hospital, Taipei

LinKou Chang Gung Memorial Hosipital, Taoyuan District